AstraZeneca puts 'for sale' sign on Wilmington campus; Army docs tell special forces to stop using malaria drug;

@FiercePharma: Still trending on our website: FDA turbocharges Glaxo's bids for new cancer drug uses. Article | Follow @FiercePharma

@CarlyHFierce: Gold-encrusted mooncakes stuffed with shark's fin "out of favor" in China; corruption crackdown has killed demand. More from Reuters | Follow @CarlyHFierce

> AstraZeneca ($AZN) has put another of its soon-to-be-vacant sites up for sale: a campus in Wilmington, DE, which encompasses 58 acres and two buildings totaling more than 350,000 square feet. Report

> Elite U.S. Army units have been told to stop taking a malaria drug, mefloquine, which the FDA linked with neurological disorders in a July alert. Report

> ViroPharma ($VPHM), working with Goldman Sachs on a possible sale via auction, could fetch a premium of up to 50%, analysts now say; Sanofi ($SNY) and Shire ($SHPG) are said to be interested. Report

> Teva Pharmaceutical Industries ($TEVA) shares have been buoyed by prospects for dividend payments, even as the company faces early competition to its multiple sclerosis blockbuster Copaxone. Report

> Transcept Pharmaceuticals ($TSPT) shareholder Retrophin offered to pay $4 per share for the company, which makes the struggling insomnia remedy Intermezzo. Report | More from FierceBiotech

> Jazz Pharmaceuticals ($JAZZ) sued Amneal Pharmaceuticals, accusing the generics maker of stepping on its patent for the narcolepsy drug Xyrem. Report (sub. req.)

> Aesthetic dermatology drugmaker Sinclair IS Pharma posted a 69% increase in profits for the year ended June 30, to $6.87 million. Report

Medical Device News

@FierceMedDev: Doctors may be overusing MRI facilities they own. More from FierceDiagnostics | Follow @FierceMedDev

@DamianFierce: Covidien plots job cuts, plant closures to save $300M. News | Follow @DamianFierce

@MarkHFierce: Agilent will split in two, keeping its growing Dx business under the current name. Press release | Follow @MarkHFierce

@MichaelGFierce: The artificial pancreas combines an insulin pump with a continuous glucose monitor. Who will get one to market first? Feature from FierceDrugDelivery | Follow @MichaelGFierce

> Roche links with Boehringer Ingelheim in companion Dx deal. Story

> GE-commissioned survey blasts neurological disease Dx delays. Item

> Edwards hit with shareholder suit over 'misleading' Sapien claims. Article

> Nanosphere snags $30.2M in stock sale. Report

Biotech News

@FierceBiotech: Popular yesterday from FierceBiomarkers: 12-year study flags new biomarker for high risk of diabetes. Article | Follow @FierceBiotech

@JohnCFierce: Google is making waves in biotech, glad Google Ventures' Krishna Yeshwant is speaking at our Oct. 15 event in Boston. Register here | Follow @JohnCFierce

@EmilyMFierce: ICYMI yesterday: Stem cell therapy protects vision in preclinical retinal disease study. More from FierceBiotech Research | Follow @EmilyMFierce

> Acceleron raises $93M as Celgene, investors rally around another biotech IPO. Report

> BioMarin spike fades as Roche CEO guns down latest takeover rumor. Story

> Wearing biotech hat, hedge fund vet Shkreli shakes the gate at Transcept. More

> Google's biotech plan: Partner with legendary CEO, tackle aging, think outside the cancer box. Article

Vaccines News

> Study links delayed vaccines to increased risk of whooping cough. More

> Unvaccinated clusters bear brunt of bad year for measles in U.S. Story

> Brain cancer vaccine data gives Agenus' stock a boost. Article

> India gives 114 kids the wrong vaccine in polio mix-up. News

> NIH trialing Sanofi H7N9 vaccine with GSK, Novartis adjuvants. Report

> Visterra advances universal flu antibody to cusp of Phase I. Item

Pharma Manufacturing News

@EricPFierce: Bad luck for this Shamrock. FDA clobbers it with a consent decree and permanent injunction. More | Follow @EricPFierce

> Hikma, partner to build $20M plant in Ethiopia. Story

> FDA uncovers big foul-ups at Ranbaxy plant. Article

> Aesica invests $48M in U.K. plant to make diabetes drugs. News

> MIT works on process to manufacture biologics in 24 hours. Item

And Finally... The roots of financial bubbles could be found in particular functions of the human brain. Report

Suggested Articles

Which rollouts might suffer most? Those that treat chronic diseases, require doctors to administer them or face current competition, analysts say.

Novartis and Incyte will put their blockbuster JAK inhibitor into phase 3 clinical trials as a possible treatment for COVID-19, the drugmakers said.

The Cannes Lions canceled its advertising creativity conference for 2020 after media reports that many large ad agencies planned to opt out.